Literature DB >> 8781586

Monitoring of occupational exposure to cytostatic anticancer agents.

M Sorsa1, D Anderson.   

Abstract

Many anticancer agents have been shown to be carcinogenic, mutagenic and teratogenic in experimental animals and in in vitro test systems. Epidemiological data on the association of second neoplasms with a specific chemotherapy treatment is available on some 30 agents, and in the case of 10 compounds the overall evidence on human carcinogenicity has been evaluated to be conclusive (Group 1: IARC, 1987 and 1990). The primary source of human exposure to anticancer drugs is from their use in therapy of cancer. However, persons employed in the manufacture, preparation and administration of the drugs to patients and in nursing patients may also be exposed. Safe handling of anticancer drugs, since the introduction of various general handling guidelines, is now good practice in hospitals, pharmacies and drug manufacturing companies of most developed countries. Careless handling of cancer chemotherapeutic agents may lead to exposure of the personnel in amounts detectable with chemical or biological methods in the body fluids or cell samples of the subjects. The exposure is typically to mixed compounds over long-term and to low exposure levels with accidental peaks. Therefore, the use of biological exposure markers is appropriate for the monitoring of such exposure patterns. The biological markers/methods for exposure assessment are either non-specific (e.g., cytogenetic damage, point mutations or 32P-post-labelling adducts in peripheral blood lymphocytes, urinary mutagenicity) or specific for a given compound (immunological methods for DNA adducts, specific analytical methods). Studies have revealed minor amounts of cyclophosphamide in the urine of pharmacy technicians and nurses handling the drug even when taking special safety precautions (Sessink et al. (1994a) J. Occup. Med., 36, 79; Sessink et al. (1994b) Arch. Env. Health, 49, 165). Another study showed surface wipe samples with measurable cyclophosphamide even away from the handling site (McDevitt et al. (1993) J. Occup. Med., 5, 57). These studies strongly implicate the importance of skin absorption as an exposure route. Also accidental spillage is never completely avoidable (Sorsa et al. (1988) Mutation Res., 204, 465-479). The potential confounders (smoking etc.), toxicokinetics of the agent(s) to be assessed and individual working practices should be carefully considered in any exposure assessment studies using human body fluid samples. Environmental monitoring on indicator cytostatics should be combined into studies designed to identify potential occupational exposure situations to anticancer agents. A properly performed study should also include dissemination of information to the workers to create a psychologically positive atmosphere for this important work.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8781586     DOI: 10.1016/0027-5107(96)00031-0

Source DB:  PubMed          Journal:  Mutat Res        ISSN: 0027-5107            Impact factor:   2.433


  13 in total

1.  Large-cell neuroendocrine cancer of the colon following rituximab-based lymphoma treatment.

Authors:  Hugh James Freeman; Peter W C Kwan; Douglas Webber
Journal:  Can J Gastroenterol       Date:  2012-01       Impact factor: 3.522

2.  Human effect monitoring in cases of occupational exposure to antineoplastic drugs: a method comparison.

Authors:  S Kevekordes; T W Gebel; M Hellwig; W Dames; H Dunkelberg
Journal:  Occup Environ Med       Date:  1998-03       Impact factor: 4.402

3.  Micronuclei and chromosome aberrations in subjects occupationally exposed to antineoplastic drugs: a multicentric approach.

Authors:  Massimo Moretti; Maria Giuseppa Grollino; Sofia Pavanello; Roberta Bonfiglioli; Milena Villarini; Massimo Appolloni; Mariella Carrieri; Laura Sabatini; Luca Dominici; Laura Stronati; Giuseppe Mastrangelo; Anna Barbieri; Cristina Fatigoni; Giovanni Battista Bartolucci; Elisabetta Ceretti; Francesca Mussi; Silvano Monarca
Journal:  Int Arch Occup Environ Health       Date:  2014-11-02       Impact factor: 3.015

4.  Development of a new method for sampling and monitoring oncology staff exposed to cyclophosphamide drug.

Authors:  Davood Panahi; Mansour Azari; Mohammad Esmaeil Akbari; Rezvan Zendehdel; Hamid Reza Mirzaei; Hossein Hatami; Yadollah Mehrabi
Journal:  Environ Monit Assess       Date:  2016-03-22       Impact factor: 2.513

5.  Genotoxic evaluation of occupational exposure to antineoplastic drugs.

Authors:  Andres Felipe Aristizabal-Pachon; Willian Orlando Castillo
Journal:  Toxicol Res       Date:  2019-12-02

6.  Occupational exposure to chemotherapy of pharmacy personnel at a single centre.

Authors:  Raveena Ramphal; Tejinder Bains; Geneviève Goulet; Régis Vaillancourt
Journal:  Can J Hosp Pharm       Date:  2015 Mar-Apr

Review 7.  Meta-analysis of chromosomal aberrations as a biomarker of exposure in healthcare workers occupationally exposed to antineoplastic drugs.

Authors:  Christine Roussel; Kristine L Witt; Peter B Shaw; Thomas H Connor
Journal:  Mutat Res Rev Mutat Res       Date:  2017-08-24       Impact factor: 5.657

8.  Immunotoxicity monitoring of hospital staff occupationally exposed to cytostatic drugs.

Authors:  Anna Biró; Zoltán Fodor; Jeno Major; Anna Tompa
Journal:  Pathol Oncol Res       Date:  2010-11-27       Impact factor: 3.201

9.  Validation of urinary excretion of cyclophosphamide as a biomarker of exposure by studying its renal clearance at high and low plasma concentrations in cancer patients.

Authors:  Maria Hedmer; Peter Höglund; Eva Cavallin-Ståhl; Maria Albin; Bo A G Jönsson
Journal:  Int Arch Occup Environ Health       Date:  2007-06-20       Impact factor: 3.015

10.  Occupational exposure to cytotoxic drugs in two UK oncology wards.

Authors:  E Ziegler; Howard J Mason; P J Baxter
Journal:  Occup Environ Med       Date:  2002-09       Impact factor: 4.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.